Literature DB >> 7512467

Individualised selection of antihypertensive therapy.

L H Opie1.   

Abstract

Theoretically, it should be possible to match the requirements of individual patients with the pharmacological and clinical properties of the large number of antihypertensive drugs now available. The concept of automatic sequential stepped-care therapy is now largely outdated, but therapy of clinically important hypertension must be initiated with one agent. Diuretics remain a first-line option in the elderly and in Black patients, as do calcium antagonists. Outcome trials are available only for the elderly, and in these the benefits of initial diuretic therapy are well documented. Nonetheless, diuretics may often need to be co-prescribed with a beta-blocker or an adrenergic modifier such as methyldopa. beta-Blockers are preferred in patients with ischaemic heart disease or enhanced adrenergic drive, while alpha-blockers are preferred in patients with blood lipid abnormalities or prostatic problems. Calcium antagonists or angiotensin converting enzyme (ACE) inhibitors are being increasingly used as initial therapy when quality of life is important and metabolic neutrality is required. Calcium antagonists are more likely to be effective first-line therapy than ACE inhibitors in patients with a high salt intake, in patients with Raynaud's disease, when angina pectoris is present, and in Black patients. ACE inhibitors are preferred for combination with diuretic agents, and in the presence of congestive heart failure or low salt intake. Experimentally, both calcium antagonists and ACE inhibitors can prevent ischaemic ventricular fibrillation and atheroma. Combination therapy between these 2 drug classes is gaining increasing acceptance because of these theoretical advantages.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512467     DOI: 10.2165/00003495-199300462-00023

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension.

Authors:  W H Sheu; A L Swislocki; B Hoffman; Y D Chen; G M Reaven
Journal:  Am J Hypertens       Date:  1991-03       Impact factor: 2.689

2.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

3.  The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study.

Authors:  A Salvetti; A Magagna; P Innocenti; F Ponzanelli; A Cagianelli; M Cipriani; E Gandolfi; C Del Prato; A M Ballestra; P Saba
Journal:  J Cardiovasc Pharmacol       Date:  1991-02       Impact factor: 3.105

Review 4.  A potential role of calcium ions in early ischemic and reperfusion arrhythmias.

Authors:  L H Opie; W A Coetzee; S C Dennis; F T Thandroyen
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

6.  Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension.

Authors:  L D Jee; L H Opie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

7.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

8.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

9.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

10.  Role of calcium antagonists in systemic hypertension.

Authors:  A Zanchetti
Journal:  Am J Cardiol       Date:  1987-01-30       Impact factor: 2.778

View more
  2 in total

Review 1.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

2.  Effects of verapamil slow release plus trandolapril combination therapy on essential hypertension.

Authors:  Ulver Derici; Sukru Sindel; Turgay Arinsoy; Musa Bali; Berna Goker; Mustafa Cemri; Enver Hasanoglu
Journal:  Curr Ther Res Clin Exp       Date:  2003-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.